Grifols at the Forefront of the Ibex 35

Grifols is once again at the forefront of the IBEX 35 ‘s advances at mid-morning, with a rise of 3.42% to 9.02 euros within a selective that at the same time advanced 0.64%. It is its fourth consecutive day in positive, although in the accumulated of the year the titles still fall more than 40%.

Of course, the price of the blood products company has rebounded 30% from the lows of 6.89 euros marked at the beginning of March.

If you want to read more about Grifols and find the latest financial news from around the world, download for free our companion app Born2Invest, available for free for both Android and iOS devices

Grifols Procleix ArboPlex Assay test

Grifols announced that its new Procleix ArboPlex Assay test has obtained the European Conformity (CE) marking under the In Vitro Diagnostic Regulation (IVDR), the first certification for an automated nucleic acid test (NAT) specifically validated to screen blood donors by detecting four important arboviruses: dengue, Zika, chikungunya and West Nile viruses.

These are the four most worrying arboviruses, all of them transmitted by mosquito vectors. Climate change and increased global connectivity have turned the geographic spread of arboviruses and gradual exposure to them into a major public health problem. In the case of the dengue virus alone, in 2023 more than 5 million cases and 5,000 deaths were recorded worldwide.

The Procleix ArboPlex Assay test uses plasma or serum samples to detect arbovirus RNA, further strengthening Grifols’ Procleix product portfolio for blood donor screening. Currently, the risk of arboviruses in blood donors is evaluated with a monoplex test, a duplex test or by a questionnaire through which donors who declare having previously traveled to or previously resided in arbovirus endemic areas are temporarily suspended.

With Procleix ArboPlex Assay, blood banks and collection centers could decide whether these deferrals are unnecessary when donors who undergo this test test negative.

Grifols 2023 accounts

On the other hand, the National Securities Market Commission (CNMV) pointed out that the blood products multinational has not yet presented the additional information that the regulator required after analyzing its accounts, but is still within the deadline to do so after the request.

“There is no new information to convey on the subject, we made a very exhaustive communication on these issues and the company is still within the deadline to be able to provide additional information,” said Rodrigo Buenventura, president of the CNMV, in statements to the press collected by Efe after his participation in a conference organized by the European Federation of Financial Analyst Societies (EFFAS) in collaboration with the Spanish Institute of Analysts and Acciona.

The regulator informed the company that it was not necessary for Grifols to reformulate its accounts, but it did ask the blood product manufacturer to publish, within a period of fifteen days, a detail of the gross operating profit (ebitda) and the net financial debts to the closing of the fiscal years 2022 and 2023 of the most relevant entities in which it has interests.

On April 1st, the blood products manufacturer Grifols began a new stage at the management level, after the new CEO, Nacho Abia, took office.

__

(Featured image by Yorgos Ntrahas via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in ESTARTEGIAS de INVESRION. A third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the originals will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us